RxDoctor Payments DataLook up a doctor →

Brian Adams, MD

Family Medicine · Fort Wayne, INNPI 1013927904

Payments from drug & device makers

$173,052in general payments, 2019–2025

Across 604 payments — averaging $286.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$144K
  • Shire North American Group Inc$22K
  • AbbVie$2K
  • Novo Nordisk$664
  • AstraZeneca$643
  • Lilly USA, LLC$556
  • plus $4K from 44 others

What the payments were for

  • Consulting fees$165,32896%
  • Food & beverage$7,7244%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$173,052 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$93,167
Medicare patients
324
Services billed
1,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,404$228,803
MounjaroTirzepatide81$111,733
Trelegy ElliptaFluticasone/Umeclidin/Vilanter138$97,945
FarxigaDapagliflozin Propanediol83$91,700
GemtesaVibegron716$86,925
JardianceEmpagliflozin327$81,459
TrulicityDulaglutide83$68,643
NuplazidPimavanserin Tartrate51$62,867
TradjentaLinagliptin255$47,323
XareltoRivaroxaban117$42,072
RexultiBrexpiprazole102$37,292
OzempicSemaglutide30$37,246
Soliqua 100-33Insulin Glargine/Lixisenatide37$36,181
MyrbetriqMirabegron200$30,708
Atorvastatin Calcium3,280$21,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$495$238,8821,436 claims
Lilly USA, LLCMounjaro, Trulicity$556$180,376164 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$234$141,643593 claims
GSKTrelegy Ellipta, Anoro Ellipta$201$106,602162 claims
AstraZenecaFarxiga, Brilinta$643$100,626162 claims
Sumitomo Pharma America, Inc.Gemtesa$98$86,925716 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$284$48,951215 claims
Johnson & JohnsonXarelto$66$42,072117 claims
Otsuka America Pharmaceutical, Inc.Rexulti$30$37,292102 claims
Novo NordiskOzempic$664$37,24630 claims
Astellas Pharma US IncMyrbetriq$107$30,708200 claims
MerckJanuvia, Janumet$187$23,69973 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →